Arrowhead Pharmaceuticals, Inc.
ARWRNASDAQHealthcare● Active
$73.67
+$0.58(+0.80%)
Market Cap$10.4B
P/E Ratio—
52W High$82.26
52W Low$14.3
Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ARWR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.93
Est. -$1.09 · +14.7%
Revenue
$0.07B
Est. $0.07B · -0.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ARWR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$1.17 | — | — | — | $0.05B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$1.09 | -$0.93 | +14.7% | $0.07B | $0.07B | -0.1% |
| ▼ Q1 FY2026 | Feb 5, 2026 | $0.60 | $0.22 | -63.3% | $0.26B | $0.21B | +23.4% |
| ▼ Q4 FY2025 | Nov 25, 2025 | -$0.11 | -$0.18 | -61.3% | $0.26B | $0.18B | +46.3% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.94 | -$1.26 | -34.0% | $0.03B | $0.15B | -82.0% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.06 | $2.75 | +4683.3% | $0.54B | $0.12B | +366.8% |
| ▼ Q1 FY2025 | Feb 10, 2025 | -$0.42 | -$1.39 | -230.9% | $0.00B | $0.02B | -86.9% |
| ▼ Q4 FY2024 | Nov 26, 2024 | -$1.05 | -$1.38 | -31.4% | $0.00B | $0.06B | -93.5% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$1.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.93
EPS Est.
-$1.09
EPS Surpr.
+14.7%
Revenue
$0.07B
Q1 FY2026
Feb 5, 2026Miss
EPS Actual
$0.22
EPS Est.
$0.60
EPS Surpr.
-63.3%
Revenue
$0.26B
Q4 FY2025
Nov 25, 2025Miss
EPS Actual
-$0.18
EPS Est.
-$0.11
EPS Surpr.
-61.3%
Revenue
$0.26B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$1.26
EPS Est.
-$0.94
EPS Surpr.
-34.0%
Revenue
$0.03B
Q2 FY2025
May 12, 2025Beat
EPS Actual
$2.75
EPS Est.
-$0.06
EPS Surpr.
+4683.3%
Revenue
$0.54B
Q1 FY2025
Feb 10, 2025Miss
EPS Actual
-$1.39
EPS Est.
-$0.42
EPS Surpr.
-230.9%
Revenue
$0.00B
Q4 FY2024
Nov 26, 2024Miss
EPS Actual
-$1.38
EPS Est.
-$1.05
EPS Surpr.
-31.4%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $-1.66 | $-0.56 | $0.00 | 3 |
| Q2 FY2027 | $-3.71 | $-1.26 | $0.00 | 5 |
| Q1 FY2027 | $-3.68 | $-1.25 | $0.00 | 3 |
| Q4 FY2026 | $-3.33 | $-1.13 | $0.00 | 6 |
| Q3 FY2026 | $-1.41 | $-1.13 | $-0.69 | 8 |
| Q2 FY2026 | $-1.56 | $-1.20 | $-0.27 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.2B | $0.4B | 5 |
| Q2 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q1 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q4 FY2026 | $0.0B | $0.1B | $0.1B | 8 |
| Q3 FY2026 | $0.0B | $0.1B | $0.2B | 9 |
| Q2 FY2026 | $0.0B | $0.1B | $0.1B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +14.7% | $79.14 | $77.95 | -1.50% |
| ▼ Q1 FY2026 | Feb 5, 2026 | -63.3% | $68.06 | $64.64 | -5.02% |
| ▼ Q4 FY2025 | Nov 25, 2025 | -61.3% | $44.26 | $46.79 | +5.72% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -34.0% | $16.31 | $16.06 | -1.53% |
| ▲ Q2 FY2025 | May 12, 2025 | +4683.3% | $13.03 | $13.97 | +7.21% |
| ▼ Q1 FY2025 | Feb 10, 2025 | -230.9% | $20.24 | $19.92 | -1.58% |
| ▼ Q4 FY2024 | Nov 26, 2024 | -31.4% | $18.79 | $21.05 | +12.03% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -137.9% | $25.00 | $25.85 | +3.40% |
Q2 FY2026-1.50%
Report Date
May 7, 2026
EPS Beat/Miss
+14.7%
Price Before
$79.14
Price After
$77.95
Q1 FY2026-5.02%
Report Date
Feb 5, 2026
EPS Beat/Miss
-63.3%
Price Before
$68.06
Price After
$64.64
Q4 FY2025+5.72%
Report Date
Nov 25, 2025
EPS Beat/Miss
-61.3%
Price Before
$44.26
Price After
$46.79
Q3 FY2025-1.53%
Report Date
Aug 7, 2025
EPS Beat/Miss
-34.0%
Price Before
$16.31
Price After
$16.06
Q2 FY2025+7.21%
Report Date
May 12, 2025
EPS Beat/Miss
+4683.3%
Price Before
$13.03
Price After
$13.97
Q1 FY2025-1.58%
Report Date
Feb 10, 2025
EPS Beat/Miss
-230.9%
Price Before
$20.24
Price After
$19.92
Q4 FY2024+12.03%
Report Date
Nov 26, 2024
EPS Beat/Miss
-31.4%
Price Before
$18.79
Price After
$21.05
Q3 FY2024+3.40%
Report Date
Aug 8, 2024
EPS Beat/Miss
-137.9%
Price Before
$25.00
Price After
$25.85
Avg Beat Reaction+2.85%
Avg Miss Reaction+2.17%
Beat Rate2 / 8 quarters
Largest Move+12.03% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ARWR ends December
Arrowhead Pharmaceuticals, Inc. (ARWR) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.93 — beating the analyst consensus of $-1.09 by +14.7%. The next ARWR earnings date is expected around September 1, 2026.
Each quarter, investors track ARWR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ARWR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ARWR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ARWR earnings · 5 questionsArrowhead Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ARWR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ARWR historically reports after market close (AMC).
ARWR earnings datewhen is ARWR earningsARWR next earnings datewhen does ARWR report earningsARWR earnings calendar
▸ Source: FMP · Arrowhead Pharmaceuticals, Inc. SEC filings · US GAAP · Arrowhead Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026